A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China).
H M Mitchell, P Hu, Y Chi...
https://pubmed.ncbi.nlm.nih.gov/9453484Actively Recruiting
Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07045857
Recurrence of H. Pylori Infection: Incidence and Influential Factors in Sohag Government
Led by Sohag University · Updated on 2025-07-01
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The trial investigates the recurrence of H. Pylori infection in patients who previously received medical treatment. It aims to determine how often the infection returns, identify factors that influence this recurrence, and evaluate the effectiveness of different treatment regimens in reducing the chance of the infection coming back. Participants are followed up after their initial successful treatment for H. Pylori infection to monitor recurrence and assess various influential factors. The study focuses on patients aged 18 to 75 years who have had confirmed H. Pylori infection and received medical treatment. This follow-up is designed to gather information over time about the infection's return. During the study, participants will be monitored for signs of H. Pylori recurrence four weeks after treatment completion. Researchers will evaluate symptoms related to the infection and perform necessary tests to check for recurrence. The main outcome measured is the rate of H. Pylori infection returning after therapy. Safety and health status will be observed throughout the follow-up period, with participation lasting according to the study timeline ending in November 2025.
CONDITIONS
Brief Title
Recurrence of H Pylori : Incidence and Influential Factors.
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- Confirmed H. pylori infection by endoscopy, biopsy, or non-invasive tests such as urea breath test or stool antigen test
- Presence of symptoms like dyspepsia, peptic ulcer disease, or other related symptoms
- Normal liver and kidney function and no significant abnormalities in blood counts
You will not qualify if you...
- Use of proton pump inhibitors, H2 blockers, bismuth, antibiotics, or other medications that affect test results within the past 4 weeks
- Severe gastrointestinal disorders including gastric cancer, inflammatory bowel disease, or recent bleeding ulcers
- Active or recent malignancies
- Unstable or severe comorbid conditions such as heart failure or liver cirrhosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Outpatient Treatment
Duration - 4 weeks after successful medical treatment
Participants who had H. Pylori infection and received medical treatment are followed up to observe recurrence and influential factors.
Follow-up visits during this period
Trial Site Locations
Total: 1 location
1
Sohag University Hospital
Sohag, Egypt
Actively Recruiting
Loading map...
Research Team
T
Thomas W Thabet, Resident
U
Usama M Abdelaal, Professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months.
T S Chen, S H Tsay, F Y Chang...
https://pubmed.ncbi.nlm.nih.gov/7548807Role of dental plaque, saliva and periodontal disease in Helicobacter pylori infection.
Pradeep S Anand, Kavitha P Kamath, Sukumaran Anil
https://pubmed.ncbi.nlm.nih.gov/24914323